First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC.

Area of Science:

• Oncology
• Clinical Research
• Biostatistics

Background:

• Limited data exist on the survival outcomes for metastatic renal cell carcinoma (mRCC) patients undergoing multiple lines of targeted therapy (TT).
• Establishing survival benchmarks is essential for informed patient counseling and effective clinical trial design in mRCC.
• Previous studies have not comprehensively analyzed outcomes across varying numbers of TT lines.

Purpose of the Study:

• To compare the survival outcomes of mRCC patients treated with one, two, or three or more lines of TT.
• To establish survival benchmarks for mRCC patients receiving sequential TT.
• To provide data for patient counseling and clinical trial design.

Main Methods:

• Analysis of data from the International mRCC Database Consortium database.
• Inclusion of 2705 mRCC patients treated with TT.
• Comparison of overall survival (OS) and progression-free survival (PFS) using proportional hazards regression, with subgroup analyses based on trial eligibility criteria.

Main Results:

• Patients receiving 2 lines (21.0 months OS) and 3+ lines (39.2 months OS) of TT showed significantly longer OS compared to those receiving 1 line (14.9 months OS).
• Multivariable analysis confirmed that 2 lines (HR=0.738) and 3+ lines (HR=0.626) of TT were associated with improved OS.
• Overall survival for all patients was 20.9 months and PFS was 7.2 months, with variations across subgroups mirroring specific clinical trial populations.

Conclusions:

• Patients with mRCC who receive multiple lines of TT experience longer survival durations.
• The established survival benchmarks offer valuable context for interpreting clinical trial results and for designing future mRCC therapeutic strategies.
• Sequential targeted therapy demonstrates a survival benefit in metastatic renal cell carcinoma.